Clarity Pharmaceuticals Health Care

$0.700 0.005 (0.72%)

High $0.72	Low $0.70	Trades 33	Turnover $39,512	Volume 56,305
30 June 2023 at 4:10pm

Register to track CU6 and receive email alerts.

Market Cap (19-Sep) $827,996,160 (700th)	Close (30-Jun) $0.70 0 (0%)	Volume (30-Jun) 56,305	Shortsold (26-May) 28,715,960 (7.70%) (37th)
52w High $5.87	52w Low $1.97	P/E -	EPS -0.28

	Subject
	CU6 CU6 Ann: Results of Meeting
	1 (current) 2 3
	CU6 CU6 Ann: Managing Director's Presentation to AGM
	CU6 CU6 Ann: Chairman's Address to Shareholders
	CU6 CU6 Ann: ESG Report
	CU6 CU6 Ann: IND approval from the FDA for theranostic SAR-Bombesin trial
	CU6 CU6 Ann: Application for quotation of securities - CU6
	CU6 CU6 Ann: Clarity Presentation -Bell Potter Healthcare Conference 2022
	CU6 CU6 Ann: Notification regarding unquoted securities - CU6
	CU6 CU6 Ann: 50% recruitment reached for Phase II prostate cancer trial
	CU6 CU6 Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	CU6 CU6 Ann: Corporate Presentation - Wilsons Drug and Device Conference
	CU6 CU6 Ann: 50% recruitment milestone reached for prostate cancer trial
	CU6 CU6 Ann: Notice of Annual General Meeting/Proxy Form
	CU6 CU6 Ann: Application for quotation of securities - CU6
	CU6 CU6 Ann: Notification of cessation of securities - CU6
	CU6 CU6 Ann: First patient treated in therapeutic prostate cancer trial
	CU6 CU6 Ann: First participant imaged in Phase II SAR-Bombesin trial
	CU6 CU6 Ann: Date of AGM
	CU6 CU6 Ann: Corporate Governance Annual Statement
	CU6 CU6 Ann: Annual Report to shareholders
	CU6 CU6 Ann: First participants imaged in SAR-Bombesin trial
	CU6 CU6 Ann: Radiopharmaceuticals Expert Joins Clarity as Chief Scientifi
	CU6 CU6 Ann: Clarity strengthens protection of the SAR-bisPSMA product
	CU6 CU6 Ann: Recruitment opens for Phase II trial in Prostate Cancer
	CU6 CU6 Ann: Preliminary Final Report
	CU6 CU6 Ann: Paediatric neuroblastoma trial advances to cohort 3
	CU6 CU6 Ann: Imaging trial in prostate cancer opens for recruitment
	CU6 CU6 Ann: Dr Andrei Iagaru joins Clarity Scientific Advisory Board
	CU6 CU6 Ann: Notification regarding unquoted securities - CU6
	CU6 CU6 Ann: Clarity expands manufacturing capabilities
	CU6 CU6 Ann: Clarity and Evergreen expand TCT manufacturing
	CU6 CU6 Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	CU6 CU6 Ann: Recruitment complete for diagnostic prostate cancer trial
	CU6 CU6 Ann: Notification of cessation of securities - CU6
	CU6 CU6 Ann: Change of Director's Interest Notice - Biggin
	CU6 CU6 Ann: Notification regarding unquoted securities - CU6
	CU6 CU6 Ann: Application for quotation of securities - CU6
	CU6 CU6 Ann: Application for quotation of securities - CU6
	CU6 CU6 Ann: Leading Australian cancer expert joins Clarity SAB
	CU6 CU6 Ann: Change of Director's Interest Notice O'Bryan-Tear
	CU6 CU6 Ann: Application for quotation of securities - CU6
	CU6 CU6 Ann: Release of Securities from Escrow
	CU6 CU6 Ann: Governance & Trading Policy Update
	CU6 CU6 Ann: IND Approval by US FDA for Phase II SAR-Bombesin trial
	CU6 CU6 Ann: Notification regarding unquoted securities - CU6
	CU6 CU6 Ann: Change of Director's Interest Notice - Thomas Ramdahl
	CU6 CU6 Ann: Change of Director's Interest Notice - Rob Thomas
	CU6 CU6 Ann: Clarity adds innovative nanobody IP
	CU6 CU6 Ann: Presentation Jefferies Biotech Summit
	CU6 CU6 Ann: Dr Neal Shore joins Clarity's CAB

Register to track CU6 and receive email alerts.

End of Day Prices

Date	Close	Volume	Change
18-Sep	$3.53	1,598,701	+0.29 (8.95%)
12-Sep	$3.24	1,527,582	+0.11 (3.51%)
11-Sep	$3.13	1,661,390	-0.04 (1.26%)
05-Sep	$3.17	1,197,820	+0.04 (1.28%)
04-Sep	$3.13	1,687,219	+0.03 (0.97%)
03-Sep	$3.10	2,046,917	+0.12 (4.03%)
29-Aug	$2.98	4,850,945	-0.20 (6.29%)
28-Aug	$3.18	2,981,913	-0.21 (6.19%)
22-Aug	$3.39	2,593,743	-0.15 (4.24%)
21-Aug	$3.54	2,763,175	-0.12 (3.28%)
15-Aug	$3.66	1,744,649	+0.04 (1.10%)
14-Aug	$3.62	2,810,384	-0.76 (17.35%)
07-Aug	$4.38	4,185,588	+0.01 (0.23%)
31-Jul	$4.37	3,417,626	+0.04 (0.92%)
30-Jul	$4.33	2,723,736	0.00 (0.00%)
8 up, 6 down, and 1 flat days